This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AMAG Pharmaceuticals' CEO Presents IDA-301 Data (Transcript)

AMAG Pharmaceuticals, Inc. (AMAG)

IDA-301 Data Conference Call

July 18, 2012 08:00 am ET

Executives



Bill Heiden – President & Chief Executive Officer

Lee Allen, MD – Chief Medical Officer



Frank Thomas – Chief Operating Officer



Amy Sullivan – Vice President, Investor Relations and Corporate Communications



Analysts

Mike – JP Morgan

Sarah – Morgan Stanley

Eun Yang – Jefferies & Company

Carol Werther – Summer Street Research Partners

Matt McKinsey – Robert W. Baird & Co.



Presentation



Operator

Good morning, my name is Justine and I will be your conference operator today. At this time I would like to welcome everyone to the AMAG Pharmaceuticals’ Conference Call. (Operator instructions.) Thank you. Vice President of Investor Relations Amy Sullivan, you may begin your conference.

Amy Sullivan

Thank you, Justine. Good morning, and welcome to the AMAG Pharmaceuticals’ Conference Call to discuss preliminary data from the second of two Phase III studies evaluating Feraheme for the treatment of iron deficiency anemia in a broad range of patients.

We issued a press release earlier this morning that contains the top line data from the study. We have focused the data relating to the key points to allow us to preserve our options to present the full dataset at appropriate medical conferences and journals in the future. If you haven’t received a copy of the release you can get it from the investors section of our website at www.amagpharma.com.

Before proceeding with this call, please be reminded that any statements we make during the course of this conference call that are other than historical facts are forward-looking statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. We want to emphasize that these forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Please refer to our recent filings with the SEC for a full review of the risks and uncertainties associated with our business.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs